Growth Metrics

Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2026)

Rigel Pharmaceuticals' quarterly Operating Leases came in at $228000.0 in Q1 2026, down 73.61% year-on-year from $864000.0 in Q1 2025, and down 42.28% quarter-over-quarter from $395000.0 in Q4 2025.

Rigel Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $228000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Operating Leases fell 73.61% year-over-year to $228000.0; the trailing twelve-month figure through Mar 2026 stood at $228000.0 (down 73.61% YoY), and the FY2025 full-year result was $395000.0, changed N/A from the prior year.
  • Operating Leases for Q1 2026 stood at $228000.0, down from $395000.0 in the prior quarter.
  • The five-year high for Operating Leases was $8.3 million in Q1 2022, with the low at $100000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $1.2 million, with a median of $592000.0 recorded in 2023.
  • Year-over-year, Operating Leases tumbled 90.34% in 2023 and soared 764.0% in 2025.
  • Tracing RIGL's Operating Leases over 5 years: stood at $972000.0 in 2022, then slumped by 70.68% to $285000.0 in 2023, then plunged by 64.91% to $100000.0 in 2024, then soared by 295.0% to $395000.0 in 2025, then slumped by 42.28% to $228000.0 in 2026.
  • The last three Operating Leases figures came in at $228000.0 (Q1 2026), $395000.0 (Q4 2025), and $556000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Rigel Pharmaceuticals 551.62 Mn 404.94 Mn 54.21 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 228,000.00
Dec 31, 2025 395,000.00
Sep 30, 2025 556,000.00
Jun 30, 2025 714,000.00
Mar 31, 2025 864,000.00
Mar 31, 2024 100,000.00
Dec 31, 2023 285,000.00
Sep 30, 2023 466,000.00
Jun 30, 2023 628,000.00
Mar 31, 2023 802,000.00
Dec 31, 2022 972,000.00
Mar 31, 2022 8.30 Mn
Dec 31, 2021 759,000.00
Sep 30, 2021 12.90 Mn
Jun 30, 2021 5.85 Mn
Mar 31, 2021 17.20 Mn
Dec 31, 2020 19.30 Mn
Sep 30, 2020 12.93 Mn
Jun 30, 2020 15.25 Mn
Mar 31, 2020 17.31 Mn
Dec 31, 2019 19.23 Mn
Sep 30, 2019 21.18 Mn
Jun 30, 2019 23.09 Mn
Mar 31, 2019 24.95 Mn